Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT)

This is a single-center, single-arm, prospective exploratory study designed to evaluate the safety and efficacy of luspatercept for the treatment of anemia following allogeneic hematopoietic stem cell transplantation in patients with acute leukemia. A total of 46 eligible subjects are planned to be enrolled. The primary efficacy endpoint is the proportion of patients achieving a hemoglobin increase of ≥1.5 g/dL at 8 weeks post-transplantation (without transfusion support) compared to baseline (the average of 3 days prior to the first dose). Secondary endpoints include assessing the impact of l

Trial Details

NCT ID
NCT07362095
Phase
PHASE1 / PHASE2
Sponsor
Zhujiang Hospital
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • Luspatercept
Locations (sample)
  • Guangzhou, Guangdong, China|23.11667,113.25

Key Eligibility Criteria

  • Clinically diagnosed with acute leukemia.
  • Has undergone allogeneic hematopoietic stem cell transplantation (allo-HSCT).
  • Expected to survive for more than 3 months from the date of signing the informed consent form.
  • Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures, and has provided written informed …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →